{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:35:15Z","timestamp":1774442115017,"version":"3.50.1"},"reference-count":36,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Oncology"],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:p>Objective. To explore the clinical value of specific miRNA in patients with acute promyelocytic leukemia. Methods. 129 patients with acute promyelocytic leukemia diagnosed in our hospital from January 2015 to January 2020 were selected as the observation group. At the same time, 74 patients with nonacute promyelocytic leukemia who underwent bone marrow aspiration were included as the control group. The expression levels of miR-126-5p and miR-13, different characteristic parameters, and prognosis were compared between the two groups, and the clinical significance of miR-126-5p and miR-13 in acute promyelocytic leukemia was analyzed. Results. The expression of miR-126-5p (<jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mn>12.31<\/a:mn>\n                        <a:mo>\u00b1<\/a:mo>\n                        <a:mn>2.25<\/a:mn>\n                     <\/a:math>\n                  <\/jats:inline-formula> versus <jats:inline-formula>\n                     <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mn>17.30<\/c:mn>\n                        <c:mo>\u00b1<\/c:mo>\n                        <c:mn>3.28<\/c:mn>\n                     <\/c:math>\n                  <\/jats:inline-formula>) and miR-13 (<jats:inline-formula>\n                     <e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\">\n                        <e:mn>16.05<\/e:mn>\n                        <e:mo>\u00b1<\/e:mo>\n                        <e:mn>3.47<\/e:mn>\n                     <\/e:math>\n                  <\/jats:inline-formula> versus 21.66\u2009\u00b1\u20092.18) in the observation group was significantly lower than that in the control group (<jats:inline-formula>\n                     <g:math xmlns:g=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\">\n                        <g:mi>P<\/g:mi>\n                        <g:mo>&lt;<\/g:mo>\n                        <g:mn>0.05<\/g:mn>\n                     <\/g:math>\n                  <\/jats:inline-formula>). The expression level of miR-126-5p was significantly correlated with lactate dehydrogenase level, HGB level, NPM1 mutant type, and complete remission (<jats:inline-formula>\n                     <i:math xmlns:i=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M5\">\n                        <i:mi>P<\/i:mi>\n                        <i:mo>&lt;<\/i:mo>\n                        <i:mn>0.05<\/i:mn>\n                     <\/i:math>\n                  <\/jats:inline-formula>). The expression level of miR-13 was significantly correlated with HGB level, NPM1 mutant type, and complete remission (<jats:inline-formula>\n                     <k:math xmlns:k=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M6\">\n                        <k:mi>P<\/k:mi>\n                        <k:mo>&lt;<\/k:mo>\n                        <k:mn>0.05<\/k:mn>\n                     <\/k:math>\n                  <\/jats:inline-formula>). Both expression levels of miR-126-5p and miR-13 were not correlated with sex, age, WBC, PLT, proportion of bone marrow primordial cells, hepatomegaly, splenomegaly, lymph node enlargement, and FLT3-ITD (<jats:inline-formula>\n                     <m:math xmlns:m=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M7\">\n                        <m:mi>P<\/m:mi>\n                        <m:mo>&gt;<\/m:mo>\n                        <m:mn>0.05<\/m:mn>\n                     <\/m:math>\n                  <\/jats:inline-formula>). Cox multivariate regression analysis showed that peripheral blood WBC, bone marrow blast cell count, and miR-126-5p and miR-13 were prognostic factors in patients with acute promyelocytic leukemia (<jats:inline-formula>\n                     <o:math xmlns:o=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M8\">\n                        <o:mi>P<\/o:mi>\n                        <o:mo>&lt;<\/o:mo>\n                        <o:mn>0.05<\/o:mn>\n                     <\/o:math>\n                  <\/jats:inline-formula>). The sensitivity, specificity, accuracy, and AUC of serum miR-126-5p prediction were 75.83%, 84.56%, 82.17%, and 0.729, respectively. The sensitivity, specificity, accuracy, and AUC of serum miR-13 prediction were 78.64%, 88.49%, 86.20% and 0.882, respectively. Conclusion. Serum miR-126-5p and miR-13 are closely related to the prognosis of patients with acute promyelocytic leukemia. Serum miR-126-5p and miR-13 can be used as reliable indexes to predict the prognosis of patients.<\/jats:p>","DOI":"10.1155\/2022\/7315879","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T19:50:08Z","timestamp":1648842608000},"page":"1-7","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Value of Serum miRNA in Patients with Acute Promyelocytic Leukemia"],"prefix":"10.1155","volume":"2022","author":[{"given":"Bei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo 454000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixin","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo 454000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo 454000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjun","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo 454000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo 454000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo 454000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Second Affiliated Hospital of Henan Polytechnic University, Jiaozuo 454000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo 454000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3234-2465","authenticated-orcid":true,"given":"Qinglin","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo 454000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2018.4440"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27178"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0699-2"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.01.018"},{"issue":"1","key":"5","first-page":"24","article-title":"Overexpression of miR-138 inhibits cell growth and induces caspase-mediated apoptosis in acute promyelocytic leukemia cell line","volume":"7","author":"S. R. Manafi","year":"2018","journal-title":"International Journal of Molecular and Cellular Medicine"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.3727\/096504019X15528367532612"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb0906-754"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2020.05.045"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1590\/1678-9199-jvatitd-2020-0123"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28292"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8050"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2017.04.007"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.19746\/j.cnki.issn.1009-2137.2020.03.016"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5522051"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S92470"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.10.125"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1039\/C8MD00316E"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2010.209"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210186"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0709313104"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa023143"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050995"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506654102"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.22099\/mbrc.2018.27625.1297"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13594"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11989"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.253"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/695754"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018023804"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14634.1"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2019.04.005"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.4103\/2277-9175.190996"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01187-5"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-190899"},{"key":"35","first-page":"301","article-title":"miR-126 promotes leukemogenesis in Inv (16) acute myeloid leukemia","volume":"130","author":"C. J. Brewer","year":"2017","journal-title":"Blood"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.4314\/ahs.v21i2.31"}],"container-title":["Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/jo\/2022\/7315879.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jo\/2022\/7315879.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jo\/2022\/7315879.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T19:50:15Z","timestamp":1648842615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/jo\/2022\/7315879\/"}},"subtitle":[],"editor":[{"given":"Qin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":36,"alternative-id":["7315879","7315879"],"URL":"https:\/\/doi.org\/10.1155\/2022\/7315879","relation":{},"ISSN":["1687-8469","1687-8450"],"issn-type":[{"value":"1687-8469","type":"electronic"},{"value":"1687-8450","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}